Precision BioSciences(DTIL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update DURHAM, N.C., May 13, 2024 -- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update. "In 2024, Precision ...